These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32199933)

  • 1. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.
    Farhadfar N; Li Y; May WS; Adams CB
    Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):246-251. PubMed ID: 32199933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
    Baig MU; Rytting M; Roth M; Morani AC; Nunez C; Lin P; Cuglievan B
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e991-e996. PubMed ID: 33480649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
    Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.
    Raedler J; Heyde S; Kolokythas M; Eichinger A; Binder V; Schmid I; Klein C; Feuchtinger T; Albert MH
    Br J Haematol; 2020 Jun; 189(6):e251-e254. PubMed ID: 32342493
    [No Abstract]   [Full Text] [Related]  

  • 5. Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
    Zhang X; Li J; Jin J; Yu W
    Ann Hematol; 2020 Feb; 99(2):395-397. PubMed ID: 31879788
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
    Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
    [No Abstract]   [Full Text] [Related]  

  • 8. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
    Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
    Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
    Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.
    Zhu Y; Dai Y; Tang X
    Ann Hematol; 2022 Nov; 101(11):2525-2528. PubMed ID: 36063200
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Effect of Venetoclax and Bendamustine in Early T-cell Precursor Acute Lymphoblastic Leukemia.
    Nguyen HDT; LE TM; Lee D; Cho HJ; Lee J; Sohn SK; Kim JG; Ham JY; Moon JH; Han HS; Kim J; Baek DW
    In Vivo; 2024; 38(4):1740-1749. PubMed ID: 38936885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
    Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
    Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Aldoss I; Yang D; Pillai R; Sanchez JF; Mei M; Aribi A; Ali H; Sandhu K; Al Malki MM; Salhotra A; Khaled S; Sun W; O'Donnell M; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
    Am J Hematol; 2019 Oct; 94(10):E253-E255. PubMed ID: 31259427
    [No Abstract]   [Full Text] [Related]  

  • 16. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
    Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
    Kong J; Chen N; Li M; Zhang J; Wu X; Zong L; Wu D; Song B; Qiu H
    Ann Hematol; 2022 Mar; 101(3):697-699. PubMed ID: 33954816
    [No Abstract]   [Full Text] [Related]  

  • 18. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant.
    Rahmat LT; Nguyen A; Abdulhaq H; Prakash S; Logan AC; Mannis GN
    Case Rep Hematol; 2018; 2018():6092646. PubMed ID: 30225152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
    Kupsh A; Arnall J; Voorhees P
    J Oncol Pharm Pract; 2020 Jul; 26(5):1274-1278. PubMed ID: 31865846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.